Adverse drug events
HRT linked with increased stroke risk, conclude Cochrane reviewers
Source: Shutterstock.com
Hormone replacement therapy has little if any benefit in the primary or secondary prevention of cardiovascular disease, say researchers
The impact of hormone replacement therapy (HRT) on cardiovascular (CV) risk is unclear. Observational studies have shown a possible protective effect whereas randomised controlled trials (RCTs) have been mixed.
The latest analysis, undertaken by the Cochrane Collaboration (online, 10 March 2015)[1], suggests that HRT has little if any benefit in the primary or secondary prevention of CV disease and causes an increase in the risk of stroke and venous thromboembolic events (VTE).
The review included 19 RCTs, of generally high quality, involving 40,410 postmenopausal women. The relative risks associated with HRT use versus non-use were 1.24 for stroke, 1.92 for any VTE and 1.81 for pulmonary embolism.
“We are confident that the results of our review are close to the true effects,” the authors note.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20068148
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.
Visit rpharms.com
Print 
PDF
Have your say
For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.